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Dr Matthew Dougherty (Philadelphia, Pa). There is no
question, the statistics don’t lie, that there is a benefit, but I’m
impressed with your data offered per thousand patients. If I read it
correctly, there is about a 2% absolute reduction in peripheral
vascular events over a 5-year period, even in the PAD group, which
seems like a pretty small number. And I wonder whether you have
done any cost–benefit analysis to achieve that 0.4% per year reduc-
tion?
Dr Richard Bulbulia. Considering major vascular events, an
economic analysis of HPS has shown that, at 2001 prices, 40 mg
simvastatin is cost effective for all study participants. And, with
patent expiry, the price of simvastatin is falling and it should be
cost-saving for all HPS participants, particularly for those with
PAD who actually derived the largest absolute benefits from statin
therapy, with an absolute reduction in MVE of around 6%.
Dr Michael Conte (Boston, Mass). Congratulations to you
and your coauthors for another outstanding contribution. For
those who are not familiar with it, the original report from the
Heart Protection Study was published a couple of years ago in The
Lancet. This is an important follow-up to that study focused on our
peripheral vascular patients, and I have a couple of questions. First,
can you tell us if the presence or absence of diabetes affected the
outcome in relation to statins? Was the apparent benefit of statins
more or less enriched in the diabetic population?
Second, can you tell us a little bit more about the timing of the
events in the PADpatients? Did you observe a uniform distribution
of risk reduction over time, or was the effect seen mostly within the
first year or two after randomization?
Finally, what can you tell us about antiplatelet therapy in the
trial?
Dr Bulbulia. The beneficial effect of simvastatin was not
influenced by the presence or absence of diabetes at baseline. A
reduction in major vascular events was seen after around 1 year of
treatment; however, in the recent Cholesterol Treatment Trialists
Meta-analysis of over 91,000 participants, benefits emerge within
the first year. Finally, the benefits seen with statin therapy were
additional to, and therefore independent of, any other treatments,Dr Eric Wahlberg (Stockholm, Sweden). Did you have a
chance to look at the patients with PAD without cardiac disease at
all? Could you also enlighten me if this paper differs anything from
your previous publication from the HPS study, besides the analysis
of the peripheral vascular events?
Dr Bulbulia. Around 2700 patients with PAD had no pre-
existing coronary artery disease at baseline, and they achieved
similar proportional benefits as those with CAD and PAD. This
presentation provides more detailed analyses of the PAD subgroup
in HPS and emphasizes that all such patients should be on a statin.
Observational studies suggest that less than one third of our
patients are currently receiving appropriate lipid-lowering therapy.
In addition, we have shown a reduction in peripheral vascular
events with statin allocation, which has not been reported in any
previous study.
Dr Thomas Lindsay (Toronto, Ontario, Canada). I would
applaud this as probably the first study that demonstrates the
benefit of statin therapy in a predominantly PAD group, so I think
it’s very important data. I have a couple of questions. First, what
was the number needed to treat in order to prevent an event in the
PAD subgroup vs the non-PAD subgroup?
Secondly, you said that the overall reduction in cholesterol was
1 mmol/L. Is there a better benefit with greater reductions in
cholesterol level? Was there a dose-response in terms of the pa-
tients’ benefit?
Third, many of these patients also have elevated triglycerides,
which are in fact, much more difficult to treat. Was the effect of
statin therapy dependent or independent of elevated triglyceride
levels?
Dr Bulbulia. The number needed to treat to prevent a first
major vascular event was 16 in the PAD subgroup and 20 in those
without PAD. The effects of statin therapy were independent of
baseline lipid profiles, including triglycerides. Finally, there is a
trend towards using higher doses of statins in high-risk patients.
Indeed the recent CTT meta-analysis suggests that an increased
reduction in LDL cholesterol may result in increased benefits.
DrLindsay.What would you say is an appropriate LDL target
level? As vascular surgeons take hold of risk reduction in our
patient population, we really need to have some target to treat to.
JOURNAL OF VASCULAR SURGERY
April 2007654 Heart Protection Study Collaborative GroupYour first slide implied the lower the better. We see the cardiolo-
gists going from what used to be levels of 3 mmol/L down to 2 for
LDL to now less than 2. Based on this data, what threshold would
you recommend for trying to get a patient’s LDL cholesterol to?
Dr Bulbulia. There should be no threshold for initiation of
statin therapy. HPS was not a target-finding study, but results from
some “more vs less” statin trials suggest that higher doses of statin
therapy will reduce cardiac and noncardiac vascular events further.
However, the question is whether the risks of side effects associated
with statins, which are dose-dependent, justify this approach.
Dr Jacob Lustgarten (Chevy Chase,Md). Did you notice any
morbidity and mortality benefits in patients who underwent sur-
statin therapy specifically in the PAD population. The major newgery? Statins are increasingly associated with a plaque stabilization
effect and a lower perioperative rate of adverse cardiac events, and
even a lower stroke risk after carotid surgery. It seems almost like
these patients should be on statins much the way -blockers are
used. You followed a large number of randomized patients. Did
you look for this effect?
Dr Bulbulia. We have not performed such an analysis, but I
am aware of the results of observational and smaller interventional
studies suggesting improved outcomes with statin therapy in the
perioperative period. However, our results clearly demonstrate
that all these patients should be on a statin before, during, and after
their operation.INVITED COMMENTARYWilliam R. Hiatt, MD, Denver, Colo
Current guidelines give a class I recommendation to lower
low-density lipoprotein (LDL) cholesterol levels below 100
mg/dL in all patients with peripheral artery disease (PAD) and a
class IIa recommendation to lower the LDL cholesterol level
below 70 mg/dL in patients who are at “very high risk of ischemic
events.”1 High-risk PAD would be defined as more than one
vascular bed involved—eg, a clinical history of concomitant coro-
nary or cerebral vascular disease. The primary evidence for these
recommendations comes from the original publication of the
Heart Protection Study that evaluated the benefits of simvastatin in
over 20,000 high-risk patients.2 There were 6748 patients with
PAD reported in the original publication, and these patients had a
reduction in fatal and nonfatal cardiovascular events with simvasta-
tin similar to that in patients with other forms of atherosclerosis. A
recent meta-analysis of statin therapy in a broad population of
high-risk patients demonstrated that there was a consistent benefit
in reduction of risk of cardiovascular events across a wide popula-
tion of patients and a wide range of baseline LDL cholesterol
levels.3 Thus there is a broad consensus to treat all patients at risk
with statin drugs, regardless of their baseline cholesterol level.
The publication of the Heart Protection Study Collaborative
Group in the Journal of Vascular Surgery focuses on the benefits offinding was a significant reduction in noncoronary revasculariza-
tions. Confirmatory findings were the consistency of the benefit
across all populations studied (including patients with PAD who
had no pre-existing coronary artery disease) and benefit regardless
of baseline LDL cholesterol level. There was no benefit of the statin
in preventing amputations, perhaps reflecting the end-stage patho-
physiology of patients who suffer limb loss.
Themessage is clear. All patients with PAD are at high risk and
meet criteria for statin therapy. The benefit of statin therapy is
primarily systemic (prevention of major cardiovascular events) but
also local (reduction of the need for revascularization).
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